Comparative Cytotoxicity of Standard of Care Treatment Drugs on Human Breast, Prostate, Colon, Cervical and Hepatic Cancer cell lines

Smera Satish¹ , Gayatri Gore² , Akshay Ganpule³ , Sangeeta Srivastava⁴ , Maithili Athavale⁵

Section:Research Paper, Product Type: Journal-Paper
Vol.7 , Issue.5 , pp.70-81, Oct-2020

Online published on Oct 31, 2020

Copyright © Smera Satish, Gayatri Gore, Akshay Ganpule, Sangeeta Srivastava, Maithili Athavale . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Currently there are various standard of care drugs used for the treatment of various cancers. Understanding effectiveness of standard treatment over a broad range of cancer cell lines helps in selecting the most appropriate drug for a particular cancer type. We have performed a comprehensive study for seven standard of care drugs namely Cisplatin, Sunitinib, Carboplatin, Doxorubicin, 5-Fluorouracil, Tamoxifen and Paclitaxel over a panel of Breast (MDAMB231, MDAMB468, T47D), Prostate (DU145, PC3, LNCaP), Colon (COLO205, COLO320DM, HCT-15), Cervical (SiHa, HeLa) and Hepatic (HEP3B) Cancer cell lines for anticancer (tested by MTT Assay) and anticancer stem cell activity (tested by Sphere Assay and Wound Healing Assay, WHA).Our MTT results have indicated that Doxorubicin and Sunitinib are highly potent drugs exhibiting highest activity on SiHa {IC50- 0.24uM (±0.28)} and COLO205 {IC50 -2.64uM (±0.09)}. Paclitaxel also demonstrated very high activity in MTT assay for all cancer types’ especially high potency on colon: COLO205 {IC50- 0.045uM (±0.03)}, COLO320DM {IC50- 0.058uM (±0.01)}, HCT15 {IC50- 0.007uM (±0.4)}. Interestingly, these three drugs have also demonstrated very good anti-CSC activity as indicated by ? 50% sphere reduction at 250nM for all cancer types and have exhibited remarkable reduction in growth (<30%) at scratch in WHA at the end of 48hrs.Overall, our findings suggest that Doxorubicin, Sunitinib and Paclitaxel have very high anticancer stem cell potential thereby qualifying to be used in combination therapy regimes.

Key-Words / Index Term :
MTT, Sphere Assay, Wound Healing Assay, Anticancer activity, Anticancer stem cell activity, Standard of care drugs

References :
[1]. Muhammad Mubeen and Suvrna G. Kini, “A Review on the Design and Development of EGFR Tyrosine Kinase Inhibitors in Cancer Therapy,” International Journal of Therapeutic Applications, Volume 5, pp. 29 - 37, 2012.
[2]. M. Greenwell and P.K.S.M. Rahman, “Medicinal Plants: Their Use in Anticancer Treatment,” International Journal of Pharmaceutical Science and Research, Volume 6(10), pp. 4103–4112, October 1, 2015.
[3]. Poornima B.N. and Farah Deeba, “Activities of Cinnamaldehyde from Boswellia Serrata on MCF-7 Breast Cancer Cell Line,” International Journal of Scientific Research in Biological Sciences, Volume 7(4), pp.35-43, August 2020.
[4]. Chih-Yang Huang,Da-Tong Ju, Chih-Fen Chang, P. Muralidhar Reddy, and Bharath Kumar Velmurugan7, “A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer,” Biomedicine (Taipei), Volume 7(4), 23, Dec 2017.
[5]. Mikhail V. Blagosklonny, “Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy,” Cell Cycle - Landes BioScience, Volume 3(8), pp. 1035-1042, Aug 2004.
[6]. Katrin Sak, “Chemotherapy and Dietary Phytochemical Agents,” Chemotherapy Research and Practice, Volume 2012, Article ID 282570, 11 pages, 2012.
[7]. Abidemi J. Akindele, Zahoor A. Wani, Sadhana Sharma, Girish Mahajan, Naresh K. Satti, Olufunmilayo O. Adeyemi, Dilip M. Mondhe, and Ajit K. Saxena1, “In Vitro and In Vivo Anticancer Activity of Root Extracts of Sansevieria libericaGerome and Labroy (Agavaceae),” Evidence-Based Complementary and Alternative Medicine, Article ID 560404, 11 pages, 2015.
[8]. Ricky W.Johnstone, Astrid A.Ruefli, Scott W.Lowe, “Apoptosis: A Link between Cancer Genetics and Chemotherapy,” Cell, Volume 108, Issue 2, pp. 153-164, 25 January 2002.
[9]. Shadia Al-Bahlani, * Buthaina Al-Dhahli, Kawther Al-Adawi, Abdurahman Al-Nabhani, and Mohamed Al-Kindi, “Platinum-Based Drugs Differentially Affect the Ultrastructure of Breast Cancer Cell Types,” BioMed Research International, Volume 2017, Article ID 3178794, 13 pages ,2017.
[10]. Shanmugam Hemaiswarya, and Mukesh Doble, “Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agents against human cervical cancer (HeLa) cell line,” Phytomedicine, Volume 20(2), pp.151-158, 2013 Jan15.
[11]. Leila Florento, Ronald Matias, Elena Tuaño, Katherine Santiago, Frederick dela Cruz, Alexander Tuazon, “Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro Cell-Based Approach,” International journal of Biomedical science, Volume 8 (1), pp. 76-80, March 2012.
[12]. Jin Wen, Han-Zhong Li, Zhi-Gang Ji and Jing Jin, “Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro,” Cancer Cell International, Volume 15(26), 7 pages, 2015.
[13]. Maithili A. Athavale, Samir S. Somaiya, Gayatri A. More, Smera Satish, Sangeeta A. Srivastava, “Comparative In-vitro cytotoxicity of red pigment extract of Serratia marcescens on breast and prostate cancer cell lines,” International Journal of Current Pharmaceutical Research, Volume 5, pp. 140-143, 2013.
[14]. Che-Hsin Lee, Cheng-Chia Yu, Bing-Yen Wang and Wen-Wei Chang,, “Tumorsphere as an effective in vitro platform for screening anticancer stem cell drugs,” Oncotarget, Volume 7( 2), pp. 1215-1226, 2015.
[15]. Katyakyini Muniandy, Sivapragasam Gothai, Woan Sean Tan, S. Suresh Kumar, Norhaizan Mohd Esa, Govindasamy Chandramohan, Khalid S. Al-Numair and Palanisamy Arulselvan, “In Vitro Wound Healing Potential of Stem Extract of Alternanthera sessilis,” Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 3142073, 13 pages, 2018.
[16]. Maithili A. Athavale, Gayatri A. More, Smera Satish and Sangeeta A. Srivastava, “Red Pigment Extract Of Serratia marcescens Inhibits Cell Proliferation At The Scratch Of Metastatic Prostate Cancer Cell lines DU145 and PC3,” World Journal of Pharmaceutical Research, Volume 7, Issue 17, pp. 951-959, 2018.
[17]. Mary J. Meegan and Niamh M. O’Boyle, “Special Issue - Anticancer Drugs,” Pharmaceuticals, Volume 12 (3), 134, 2019.
[18]. Bray Denard, Sharon Jiang, Yan Peng3 and Jin Ye1, “CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy,” BMC Cancer, Volume 18(813), 7 pages, 2018.
[19]. Nicholas J. Robert, Mansoor N. Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet S. Copur, Adam M. Brufsky, Susan E. Minton, Jeffrey K. Giguere, John W. Smith, Paul D. Richards, Diana Gernhardt, Xin Huang, Katherine F. Liau, Kenneth A. Kern and John Davis, “Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial,” Clinical Breast Cancer, Volume 11(2), pp. 82–92, 2011 Apr.
[20]. Taro Shiga and Makoto Hiraide, “Cardiac Toxicities of 5-Fluorouracil and Other Fluoropyrimidines,” Current Treatment Options in Oncology, Volume 21 (27), 21 pages, 2020.
[21]. O. Guérin, P. Formento, C. Lo Nigro, P. Hofman, J. L. Fischel, M. C. Etienne-Grimaldi, M. Merlano, J. M. Ferrero and G. Milano,” Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer,” Journal of Cancer Research and Clinical Oncology , Volume 134, pp. 51–57, 2008.
[22]. F J Zhao, S Zhang, Z M Yu, S J Xia & H Li, “Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyl transferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer,” Prostate Cancer and Prostatic Diseases, Volume 12, pp. 166–171, 2009.
[23]. Colombo, Monica Lupi, Francesca Falcetta, Daniele Forestieri, Maurizio D’Incalci, Paolo Ubezio, “Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells,” Cancer Chemotherapy Pharmacology, Volume 67 (2), pp. 369–379, 2011.
[24]. Riku Koivusalo and Sakari Hietanen, “The Cytotoxicity of Chemotherapy Drugs Varies in Cervical Cancer Cells Depending on the p53 Status,” Cancer Biology & Therapy, Volume 3(11), pp.1177-1183, November 2004.
[25]. Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takuji Okusaka, Hiroshi Ishii and Junji Furuse, “Chemotherapy for hepatocellular carcinoma: current status and future perspectives,” Japanese Journal of Clinical Oncology, Volume 48(2), pp. 103–114, 2018.
[26]. Rasheena Edmondson, Jessica Jenkins Broglie, Audrey F. Adcock, and Liju Yang, “Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors,” Assay Drug Development Technology, Volume 12(4), pp. 207–218, 2014 May.
[27]. Hisham F. Bahmad, Katia Cheaito, Reda M. Chalhoub, Ola Hadadeh, Alissar Monzer, Farah Ballout, Albert El-Hajj, Deborah Mukherji, Yen-Nien Liu, Georges Daoud and Wassim Abou-Kheir, “Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells,” Frontiers in Oncology, Volume 8 (347), 14 pages, 2018.
[28]. Jordi Pijuan, Carla Barceló, David F. Moreno, Oscar Maiques, Pol Sisó, Rosa M. Marti, Anna Macià and Anaïs Panosa, “In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis,” Frontiers in Cell and Developmental Biology, Volume 7 (107), 16 pages, 14 June 2019.
[29]. VOLKER SCHIRRMACHER, “From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review),” INTERNATIONAL JOURNAL OF ONCOLOGY, Volume 54, pp. 407-419, 2019.
[30]. Tram Anh Tran, Lisa Kinch, Samuel Peña-Llopis, Lutz Kockel, Nick Grishin, Huaqi Jiang and James Brugarolas, “Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1,” Molecular and Cellular Biology, Volume 33(19), pp. 3762–3779, 2013 October.
[31]. Graziele Fonseca de Sousa, Samarina Rodrigues Wlodarczyk and Gisele Monteiro, “Carboplatin: molecular mechanisms of action associated with chemoresistance,” Brazilian Journal of Pharmaceutical Sciences, Volume 50 (4), pp. 693-701, Oct/Dec 2014.
[32]. Shaloam Dasari and Paul Bernard Tchounwou,”Cisplatin in cancer therapy: molecular mechanisms of action,” European Journal of Pharmacology, Volume 740 , pp. 364–378, 2014 Oct 5.
[33]. Fan Yang, Sheila S. Teves, Christopher J. Kemp, and Steven Henikoff, “Doxorubicin, DNA torsion, and chromatin dynamics,” Biochimica et Biophysica Acta, Volume 1845 (1), pp. 84–89, 2014 Jan.
[34]. Michael B. Sporn and Scott M. Lippman, “Agents for Chemoprevention and Their Mechanism of Action,” Holland-Frei Cancer Medicine, 6th edition.
[35]. Ning Zhang, Ying Yin, Sheng-Jie Xu and Wei-Shan Chen, “5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies,” Molecules, Volume 13(8), pp. 1551–1569, 2008 August.
[36]. Beth A. Weaver,” How Taxol/paclitaxel kills cancer cells,” Molecular Biology of the Cell, Volume 25(18), pp. 2677–2681, 2014 Sep 15.
[37]. Lan Thi Hanh Phi, Ita Novita Sari, Ying-Gui Yang, Sang-Hyun Lee, Nayoung Jun, Kwang Seock Kim, Yun Kyung Lee, and Hyog Young Kwon, “Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment,” Stem Cells International, Volume 2018, Article ID 5416923, 16 pages, 2018.